SureTrader Stock Hero Advertisement
Home > Boards > US OTC > Biotechs >

NeoStem (NBS)

Add NBS Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator andy e
Search This Board:
Last Post: 4/25/2015 9:57:43 PM - Followers: 107 - Board type: Free - Posts Today: 7

NeoStem, Inc (NBS) 





Company Information:

420 Lexington Avenue
Suite 450

New York, New York 10170

Telephone: 212-584-4180
Fax: 646-514-7787


CIK:  0000320017


NeoStem, Inc. (“we,” “NeoStem” or the “Company”) is a leader in the emerging cellular therapy industry. Cellular therapy addresses the process by which new cells are introduced into a tissue to prevent or treat disease, or regenerate damaged or aged tissue, and comprises a separate therapeutic technology platform in addition to the current three pillars of healthcare: pharmaceuticals, biologics and medical devices. Modern cell-based therapies have progressed from the first recorded human to human blood transfusion 200 years ago through to the advanced cellular therapies of today including bone marrow and organ transplantation, tissue banking and reproductive in vitro fertilization and future therapies being investigated to treat cancer, cardiologic, neurologic, ophthalmic and orthopedic diseases among others. We anticipate that cellular therapies will have a large role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society.
Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization (“CDMO”) providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation.
Progenitor Cell Therapy, LLC, our wholly owned subsidiary (“PCT”), is a leading CDMO in the cellular therapy industry. Since its inception in 1997, PCT has provided pre-clinical and clinical current Good Manufacturing Practice (“cGMP”) development and manufacturing services to over 100 clients advancing regenerative medicine product candidates through rigorous quality standards all the way through to human testing. PCT has two cGMP, state-of-the art cell therapy research, development, and manufacturing facilities in New Jersey and California, serving the cell therapy community with integrated and regulatory compliant distribution capabilities. Its core competencies in the cellular therapy industry include manufacturing of cell therapy-based products, product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery and consulting services.
Our wholly-owned subsidiary, Amorcyte, LLC (“Amorcyte”), which we acquired in October 2011, is developing our own cell therapy, AMR-001, for the treatment of cardiovascular disease. AMR-001 represents our most clinically advanced therapeutic product candidate and enrollment for our Phase 2 PreSERVE clinical trial to investigate AMR-001's safety and efficacy in preserving heart function after a heart attack in a particular type of post Acute Myocardial Infarction (“AMI”) patients commenced in 2012. We expect to complete enrollment for this study in 2013 with the first data readout available six to eight months thereafter. If approved by the U.S. Food and Drug Administration ("FDA") and/or other worldwide regulatory agencies, AMR-001 would address a significant unmet medical need in the treatment of AMI, potentially improving the quality and longevity of life for those afflicted, and position the Company to capture a meaningful share of the worldwide AMI market.
Through our majority-owned subsidiary, Athelos Corporation (“Athelos”), we are collaborating with Becton-Dickinson in early stage clinical development of a therapy utilizing T-cells, collaborating for autoimmune and inflammatory conditions, including but not limited to, graft vs. host disease, type 1 diabetes, steroid resistant asthma, lupus, multiple sclerosis and solid organ transplant rejection. We plan to investigate the clinical feasibility of nTreg-based therapeutics to prevent and/or treat type 1 diabetes, graft vs. host disease, steroid resistant asthma, lupus, multiple sclerosis and solid organ transplant rejection and expect to file an Investigational New Drug Application ("IND") with the FDA in 2013 and commence human clinical studies in one of these disease conditions thereafter.
Our pre-clinical assets include our VSEL TM (Very Small Embryonic Like) Technology platform for which we expect to file an IND with the FDA in late 2013 or early 2014 to initiate an National Institutes of Health ("NIH") funded human clinical studies treating periodontitis with VSELs TM . We are also working on a Department of Defense funded study of VSELs TM and mesenchymal stem cells for the treatment of chronic wounds.
NeoStem's origins are in adult stem cell collection and storage and we believe that as new therapeutics are developed utilizing one's own stored cells (autologous), the market penetration rate for the collection and storage business may rise sharply from its current low single digits percentage level allowing our developing a network to scale rapidly if the demand grows.
We believe that NeoStem is ideally positioned to be an integrated leader in the cell therapy industry. We have significant basic research and development capabilities, manufacturing facilities on both the east and west coast of the United States, the support of regulatory and logistical expertise and a talented and experienced clinical team. We believe this expertise will allow us to achieve our mission of becoming the premier cell therapy company.






Feature Stories:



Recent News:






Transfer Agent:

Continental Stock Transfer & Trust Company
17 Battery Place
New York, NY 10004




Investor Relations:

Robin L. Smith
Phone: +1 (212) 584-4174










All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.


Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.


Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement:




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#1743   thanks again for being so honest. at some hbhmb 04/25/15 09:57:43 PM
#1742   thanks for the comment, keeping an eye out hbhmb 04/25/15 09:53:56 PM
#1741   I noticed your comment about NBS trading on Potomac 04/25/15 08:41:46 PM
#1740   LOL that is just about where I am Viperciara 04/25/15 12:34:19 PM
#1739   I'm with ya Viper..been here for at least andy e 04/25/15 12:21:32 PM
#1738   I think it all has to do with Viperciara 04/25/15 12:08:18 PM
#1737   hi, you seem like a reasonable, rational sort hbhmb 04/25/15 11:49:54 AM
#1736   I would be thrilled for $10 Viperciara 04/23/15 05:25:38 PM
#1735   Haven't seen this on IH board? winnersworld 04/23/15 04:10:29 PM
#1734 winnersworld 04/23/15 03:56:21 PM
#1733 winnersworld 04/23/15 03:49:08 PM
#1732   NBS mentioned here!(From THE STREET) Viperciara 04/23/15 02:34:04 PM
#1731   My friend Tanya posted this on my facebook Viperciara 04/21/15 05:42:35 PM
#1730   NBS will be busy tomorrow! We have 2 Viperciara 04/21/15 08:54:41 AM
#1729   NeoStem Announces Expanded Cell Therapy Manufacturing Relationship With Viperciara 04/20/15 07:52:32 AM
#1728   This has been added for you to watch Viperciara 04/16/15 03:42:05 PM
#1727   Carl Ichan thinks Neostem is good or why Viperciara 04/16/15 08:05:50 AM
#1726   On NeoStem site they have now updated the Viperciara 04/16/15 07:10:02 AM
#1725   Don't forget PCT! Viperciara 04/15/15 05:56:45 AM
#1724   NBS will be busy today! Viperciara 04/15/15 05:50:03 AM
#1723   I think everyone is hoping for a partnership, Viperciara 04/13/15 01:45:30 PM
#1722   Why the PPS is guess jeffsimon99 04/13/15 11:20:58 AM
#1721   This is very interesting! I guess maybe it Viperciara 04/13/15 07:00:20 AM
#1720   Oh I agree Andy E! My PPS right Viperciara 04/13/15 06:53:24 AM
#1719,AAABsp7 Viperciara 04/13/15 06:44:38 AM
#1718   LOL..I hear that.....been here before the R/S, average andy e 04/12/15 04:45:18 PM
#1717   I believe also that is what has brought Viperciara 04/11/15 11:13:55 AM
#1716   Baxter would be perfect! I also think one Viperciara 04/11/15 11:08:50 AM
#1715   IMO fear of financing has brought it from jeffsimon99 04/10/15 07:06:43 PM
#1714   I half expect a partnership with Baxter anyday jeffsimon99 04/10/15 07:04:50 PM
#1713   Neostem, Inc. (NASDAQ:NBS) has traded 1.4% of the Viperciara 04/10/15 04:14:57 PM
#1712   thank you for your honest reply. will hbhmb 04/10/15 01:43:13 PM
#1711   Remember NBS is here today! Viperciara 04/10/15 06:12:40 AM
#1710   Honestly IMO I think it is because we Viperciara 04/10/15 06:05:07 AM
#1709   thinking of buying but could someone enlighten me hbhmb 04/09/15 09:27:33 PM
#1708   Here is a good article>> Viperciara 04/09/15 03:55:26 PM
#1707   NeoStem Announces Extension of Study Under Grant from Viperciara 04/09/15 07:47:51 AM
#1706   You are right! NBS is really starting to Viperciara 04/08/15 06:36:31 PM
#1705   Re: Athersys, a client of Neostem.... jeffsimon99 04/08/15 03:24:46 PM
#1704   Here's a good start, and we should stay Viperciara 04/08/15 07:26:24 AM
#1703   Hold tight the PPS will start to rise! Viperciara 04/07/15 06:09:47 AM
#1702   PCT Conference Attendance > Viperciara 04/06/15 08:54:22 AM
#1701   NBS has 6 new events for April!>>> Viperciara 04/06/15 08:53:44 AM
#1700   Happy Easter and Pray for our troops! Viperciara 04/05/15 07:00:30 AM
#1699   He invertido muy fuerte en esta acción, con tireur 04/03/15 01:29:08 PM
#1698   Here is another story! Just great! Viperciara 04/03/15 06:12:02 AM
#1697   Here's an excellent interview of Neostem's CEO Dr.David Viperciara 04/03/15 06:10:49 AM
#1696   This will also help NBS! Viperciara 04/02/15 04:52:51 PM
#1695   Dr. Adel Nada leads the development of NBS-03, Viperciara 04/02/15 04:51:12 PM
#1694   EVA Dimensions, LLC upgrades NEOSTEM INC from HOLD Viperciara 04/02/15 04:49:22 PM